CN106309616A - Medicine with hypolipidemic effect - Google Patents
Medicine with hypolipidemic effect Download PDFInfo
- Publication number
- CN106309616A CN106309616A CN201610950085.9A CN201610950085A CN106309616A CN 106309616 A CN106309616 A CN 106309616A CN 201610950085 A CN201610950085 A CN 201610950085A CN 106309616 A CN106309616 A CN 106309616A
- Authority
- CN
- China
- Prior art keywords
- medicine
- water
- alcohol
- lipid
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000000055 hyoplipidemic effect Effects 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000001914 filtration Methods 0.000 claims abstract description 13
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000009835 boiling Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000010411 cooking Methods 0.000 abstract description 5
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000000227 grinding Methods 0.000 abstract 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 abstract 1
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000010076 mixing by material Methods 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000693079 Maloideae Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine with hypolipidemic effect. The medicine is characterized by being prepared from the following raw materials in parts by weight: loquat, hawthorn, mulberry leaf, chrysanthemum and pueraria lobate at the ratio of 1:1:1:1:1. A preparation method comprises the following steps of: 1) grinding and evenly mixing raw materials taken according to the proportion of raw materials, boiling with water, then filtering, performing alcohol cooking and then filtering, and combining the filtrates of twice; or grinding and evenly mixing raw materials taken according to the proportion of raw materials, performing alcohol cooking, then filtering, boiling with water and then filtering, and combining the filtrates of twice; and 2) performing alcohol removal on the filtrate and concentrating, and adding or adding no pharmaceutical excipients according to the dosage of finished products, thus producing the finished medicine. Experiments proved that the medicine has the hypolipidemic effect.
Description
Technical field
The present invention relates to biomedicine technical field, particularly to a kind of medicine with lipid-lowering effect.
Background technology
Hyperlipidemia is a kind of common disease, is that human body lipid metabolism is not normal caused, refers mainly to T-CHOL in serum, sweet
Oil three esters and low-density lipoprotein white level is too high or hdl level is too low.Hyperlipidemia is the most clinical
Symptom, it is invisible, gradually row to the infringement of health, and is general.Because hyperlipidemia can accelerate tremulous pulse medicated porridge sample
Hardening, once artery occlusion, a lot of disease will be caused, such as cardiovascular and cerebrovascular disease, nephropathy, hepatic disease etc..Cardiovascular and cerebrovascular vessel
Disease is the main cause that middle-aged and elderly people is lethal, is the number one killer threatening human health.Add up according to World Health Organization (WHO), every year
About 17,000,000 people die from this chronic disease, account for about the 30% of the total death toll in the whole world.In other words, the most every 3 the dead
In, just there is 1 to be caused by cardiovascular disease.
The medicine being currently used for blood fat reducing is a lot, but in clinic, does not highlight the medicine of curative effect, therefore market in urgent need
Exploitation one treats hyperlipidemic conditions medicine.
Folium Eriobotryae, the ancient entitled reed Fructus Citri tangerinae of Chinese, have another name called gold ball or reed branch, it is a genus of the Maloideae in Rosaceae, for
Evergreen dungarunga.The Folium Eriobotryae of research display at present has reduction body fat, anti-inflammatory, antitumor, blood sugar lowering and improves abnormal generation
The curative effect thanked.
Fructus Crataegi is natural lipid lowerers, mainly contains Crataegolic acid, citric acid, steatolysis acid, vitamin C, flavone, carbon water
The compositions such as compound, have expansion blood vessel, improve microcirculation, reduce blood pressure, promote that Cholesterol Excretion reduces the diseases prevention of blood fat
Health preserving effect.
Folium Mori are the dried leaves of moraceae plants Mulberry, and Folium Mori are just answered by the traditional Chinese medical science as the Chinese medicine for the treatment of diabetes since ancient times
For clinic.A lot of to the research report of Folium Mori in recent years, wherein polysaccharides of Folium Mori and polypeptide have good blood sugar lowering and blood fat reducing
Effect.
Flos Chrysanthemi, is the perennial root herbaceous plant of Compositae, Chrysanthemum in Plant Taxonomy.For anemopyretic cold, headache
Dizziness, conjunctival congestion and swelling pain search, eyes is dim-sighted.
Radix Puerariae has the effect improving brain blood circulation, to the headache caused because of hypertension, dizziness, tinnitus and pain in the low back and legs
Have etc. symptom and preferably alleviate effect.
Summary of the invention
The present invention comes from theory of Chinese medical science, sums up experience in many ways, has been developed into a kind of medicine with lipid-lowering effect, this medicine
Thing is pure Chinese medicinal preparation, and experiment proof can be substantially reduced T-CHOL in blood, triglyceride, low density lipoprotein, LDL and high density
Lipoprotein, and determined curative effect, safely and effectively.
Present invention aim at providing a kind of medicine with lipid-lowering effect, to provide one safely and effectively medicine to select
Selecting, in terms of blood fat reducing treatment, application is clinically.
A kind of medicine with lipid-lowering effect, it is characterised in that be prepared from by the raw material of following weight portion:
Folium Eriobotryae: Fructus Crataegi: Folium Mori: Flos Chrysanthemi: Radix Puerariae=1:1:1:1:1.
There is the medicine of lipid-lowering effect, it is characterised in that preparation method comprises the steps of
1) take raw material pulverizing mixing by material rate, filter with filtering after decocting in water after alcohol boils again, merge the filtrate of twice;
Or after taking raw material pulverizing mixing by material rate, after the side filtered successively extracts, merge after boiling after filtering again decocting in water with alcohol
The filtrate of twice;Described alcohol is the ethanol water of 70%-100% volume ratio.
2) carry out filtrate, except alcohol, concentration, adding further according to finished dosage forms or making finished product without excipient substance.
It is the ethanol water of 70%-100% in described alcohol.
Detailed description of the invention
In order to make content of the present invention easily facilitate understanding, below in conjunction with detailed description of the invention to of the present invention
Technical scheme is described further, but the present invention is not limited only to this.
Embodiment 1
Pharmaceutical composition extracts
Take Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, Flos Chrysanthemi 10g, Radix Puerariae 10g, pulverize mixing, with 1000 mL (1:20 solid-liquid ratio)
70% ethanol percolation 1h, afterwards 90 DEG C of oil bath reflux, extract, 2h, stands 12h, filters away residue.
Take Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, Flos Chrysanthemi 10g, Radix Puerariae 10g, pulverize mixing, by 1500 mL (1:30 feed liquid
Than) water percolation 1h, afterwards 100 DEG C of oil bath reflux, extract, 2h, stand 12h, filter away residue.
Then twice extract filtrate being merged, rotation is evaporated off ethanol and is concentrated into suitable concn.
According to the method described above, Folium Eriobotryae, Fructus Crataegi and Folium Mori are extracted respectively.
Zoopery
The kunming mice of 20-30g is randomly divided into normal group, matched group, Folium Eriobotryae group, Fructus Crataegi group, Folium Mori group, high dose group, in
Dosage group, low dose group, simvastatin group, often group 5, every day, free diet high lipid food, gave with each 200ul dosage every day
Medicine once, successive administration 2 weeks.Eyeball takes blood, with T-CHOL (TC), triglyceride (TG), high density lipoprotein (HDL-C),
Low density lipoprotein, LDL (LDL-C) test kit detects each value, detects T-CHOL and the suction of triglyceride at microplate reader 510 nm
Light value, detects high density lipoprotein and low density lipoprotein, LDL light absorption value at 546 nm, calculates mice according to the formula of test kit
The value of T-CHOL, triglyceride, high density lipoprotein and low density lipoprotein, LDL, result is as shown in table 1.
Shown in chart 1, between Folium Eriobotryae group, Fructus Crataegi group and Folium Mori group group, indices does not has significant difference, and hyperlipidemia model group is each
Index is compared, and relatively has rising more by a small margin;But compositions high dose group relatively in dosage group, low dose group and pungent cut down him
Spit of fland group, it is possible to significantly decrease T-CHOL, triglyceride and low density lipoprotein, LDL content, high density lipoprotein increasing content.
To sum up, compositions high dose can effective effect for reducing fat.
Embodiment 2
Beverage
Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, Flos Chrysanthemi 10g, Radix Puerariae 10g, mix homogeneously after pulverizing, (1:20 expects to use water-boiling method
Liquor ratio) extract, after by filtering residue with after 70% ethanol water (1:30 solid-liquid ratio) reflux, extract, filtration, united extraction liquid, be concentrated into
In right amount, extract thick paste, drying under reduced pressure, pulverize, obtain dry extract.
Take above-mentioned dry extract, routinely process, i.e. comprise allotment-homogenizing-degassing-pasteurize-
The steps such as fill-cooling, i.e. can get finished beverage.
Embodiment 3
Mixture
Take mix homogeneously after Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, each two parts of pulverizing of Flos Chrysanthemi 10g, Radix Puerariae 10g, be respectively adopted water
Decocting method (1:15 solid-liquid ratio) and ethanol solution (95%) (1:20 solid-liquid ratio) cooking method united extraction liquid, recovered under reduced pressure second after filtration
Alcohol, to without ethanol taste, cold preservation 24h, Aspirate supernatant, adds sodium benzoate 0.3%, ethyl hydroxybenzoate 0.02%, boils little half
Time, with distilled water regulation to total amount, cooling, filter, sterilizing, thus obtaining the product.
Embodiment 4
Capsule
After taking Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, each two parts of pulverizing of Flos Chrysanthemi 10g, Radix Puerariae 10g, mix homogeneously is equally divided into two
Part, it is respectively adopted decocting cooking method (1:18 solid-liquid ratio) and ethanol solution (85%) (1:25 solid-liquid ratio) cooking method united extraction liquid, concentrates
To in right amount, extract thick paste, drying under reduced pressure, pulverize, obtain dry extract.
Take above-mentioned dry extract, add Pulvis Talci, starch, mix homogeneously according to common process, pelletize, encapsulated, to obtain final product
Capsule.
Embodiment 5
Tablet
Take mix homogeneously after Folium Eriobotryae 10g, Fructus Crataegi 10g, Folium Mori 10g, each two parts of pulverizing of Flos Chrysanthemi 10g, Radix Puerariae 10g, use ethanol molten
Liquid (80%) boil (1:27 solid-liquid ratio) extract, after by filtering residue with decocting in water (1:20 solid-liquid ratio) extract after filter, merging filtrate afterwards,
Being concentrated into appropriate, be spray-dried, dried cream powder adds right amount of auxiliary materials, and mixing is crossed 60 mesh sieves, tabletting, coating, to be obtained final product.
Claims (3)
1. a medicine with lipid-lowering effect, it is characterised in that be prepared from by the raw material of following weight portion:
Folium Eriobotryae: Fructus Crataegi: Folium Mori: Flos Chrysanthemi: Radix Puerariae=1:1:1:1:1.
There is the medicine of lipid-lowering effect the most as claimed in claim 1, it is characterised in that preparation method comprises the steps of
1) by material rate take raw material pulverizing mixing, be equally divided into two parts, after portion decocting in water after filtration, another part of alcohol boil after mistake
Filter, merges the filtrate of twice;
Or after taking the pulverizing mixing of raw material pulverizing blend feedstock by material rate, filter or decocting in water after filtering again decocting in water with alcohol after boiling
After the method that rear filtration is filtered after alcohol boils again is successively extracted, merge the filtrate of twice;
2) carry out filtrate, except alcohol, concentration, adding or without pharmaceutically acceptable excipient substance system further according to finished dosage forms
Become finished product.
There is the medicine of lipid-lowering effect the most as claimed in claim 2, it is characterised in that described alcohol is 70%-100% volume
The ethanol water of ratio.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610950085.9A CN106309616A (en) | 2016-11-03 | 2016-11-03 | Medicine with hypolipidemic effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610950085.9A CN106309616A (en) | 2016-11-03 | 2016-11-03 | Medicine with hypolipidemic effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106309616A true CN106309616A (en) | 2017-01-11 |
Family
ID=57818747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610950085.9A Pending CN106309616A (en) | 2016-11-03 | 2016-11-03 | Medicine with hypolipidemic effect |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106309616A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110771761A (en) * | 2019-11-06 | 2020-02-11 | 合肥工业大学 | Radix puerariae and chrysanthemum morifolium compound beverage with auxiliary blood fat reducing effect |
-
2016
- 2016-11-03 CN CN201610950085.9A patent/CN106309616A/en active Pending
Non-Patent Citations (3)
Title |
---|
WONDER_2012X: "妙用山楂可降脂", 《HTTPS://WENKU.BAIDU.COM/VIEW/E4F354E7D15ABE23482F4DB7.HTML》 * |
刘庆春: "《糖尿病就这样吃》", 31 March 2013, 中华工商联合出版社 * |
陈冰等: "《肥胖症药膳》", 28 February 2003, 科学技术文献出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110771761A (en) * | 2019-11-06 | 2020-02-11 | 合肥工业大学 | Radix puerariae and chrysanthemum morifolium compound beverage with auxiliary blood fat reducing effect |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
CN102652801A (en) | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications | |
CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
CN101518595A (en) | Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof | |
CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
CN102813765A (en) | Method for preparing Zhixinkang preparation | |
CN104666643B (en) | A kind of compound snow chrysanthemum product and its preparation method and application | |
CN103479691A (en) | Lipid-decreasing liver protection traditional Chinese medicine composition | |
CN105770462A (en) | Healthcare tea with blood lipid reducing function | |
CN104664369B (en) | A kind of Radix et Rhizoma Gynurae divaricatae health food of blood pressure lowering uric acid resisting and preparation method thereof | |
CN104225503A (en) | Maca compound traditional Chinese herb preparation and preparation method thereof | |
CN103893389A (en) | Traditional Chinese medicinal tea drink for reducing blood pressure | |
CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
CN106309616A (en) | Medicine with hypolipidemic effect | |
CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
CN102631425B (en) | Mongolian medicine for treating dyslipidemia | |
CN102283884A (en) | Notoginseng root emblic leafflower fruit composition and application | |
CN101822705A (en) | Total platycodin and application of monomer platycodin D in antialcoholic drugs | |
CN103505664A (en) | Blood lipid reducing composition containing semen cassiae and preparation method of composition | |
CN103505518A (en) | Blood lipid reducing composition containing kudzuvine root and preparation method of composition | |
CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
CN104906243A (en) | Traditional Chinese medicine compound with liver protection function |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |
|
RJ01 | Rejection of invention patent application after publication |